Community Home

Latest Shared Files

Community Blogs

  • A Message from the President Last month, we witnessed the monumental FDA approval of lifileucel, a first-in-class tumor infiltrating lymphocyte (TIL) therapy, for patients with unresectable or metastatic melanoma. Notably, the approval of lifileucel ...

  • Inside this Issue: Letter from the Editor | JITC Editor Picks | JITC Meet-the-Editor Session | Popular Archive Articles Letter from the Editor Hello JITC Readers, ...

  • The Society for Immunotherapy of Cancer (SITC) is pleased to present a summary of the U.S. Food & Drug Administration (FDA) Meeting of the Oncologic Drugs Advisory Committee (ODAC) . Below is a recap of highlighted research presented from ...

    2 people recommend this.
  • The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Clinical/Translational Cancer Immunotherapy co-Section Editor Dr. Jason Luke . “Clinical and molecular features of acquired resistance ...

  • SITC 2024 Advances in Cancer Immunotherapy Series We’re excited to announce SITC’s 2024 Advances in Cancer Immunotherapy (ACI) educational series, which offers in-depth clinical training in immunotherapy treatment for a variety of disease states ...